What impact does therapy selection have on the course of clinical outcomes for recurrent gliomas?

Author:

Özkan Oğuzcan,Geçgel AslıORCID,Pınar Açar Fatma,Karaca Burçak,Ali Şanlı Ulus

Abstract

Aim: The most prevalent primary malignant brain tumor in humans is called glioblastoma (GBM). The prognosis is still dismal despite vigorous multimodal treatment, and many patients pass away from local recurrence. Recurrence happens in almost all cancers, even with state-of-the-art techniques and ideal multidisciplinary therapies comprising conformal radiotherapy, maximal surgical resection, and systemic medications. The development of effective medications for the treatment of recurrent glioblastoma is severely hampered by molecular heterogeneity and treatment-associated inherited or acquired resistance. Materials and methods: Twenty patients with recurrent gliomas were included in the study out of the 133 patients who had a glioma diagnosis between 2015 and 2021. Information was gathered from the patient's records and documentation. Results: Relapses occurred on average after 30.1 (range: 5.7-182.6) months. The average patient age upon diagnosis was 51 (range: 24-68). Males made up 65% of the patients. Systemic treatment was given to 17 individuals (85%). 70.5% of patients preferred the bevacizumab+irinotecan (BEV+IRI) regimen as their first-line treatment. Carmustine (5.5%) and temozolomide rechallenge (23.5%) were the other regimens. Patients who underwent systemic treatment following a relapse had an average overall survival of 8.1 months. 53.8% was the 6-month OS for patients following recurrence. Discussion: Consequently, these patients have low systemic treatment effectiveness. Treatment results that are curative are uncommon. The influence of the proposed treatment on performance status and quality of life ought to be taken into account, regardless of the severity of the disease. A less risky regimen or active surveillance may be beneficial for patients with gliomas that do not show targetable pathological alterations, as there was no statistically significant difference seen when progression-free survival lengths were evaluated. It is necessary to develop customized treatments. Targeted therapy development requires large scale investigations looking into genetic alterations.

Publisher

MedCrave Group Kft.

Reference18 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3